Pfizer gets mixed results against IPP claims
The state antitrust claims brought by a class of indirect purchasers of Pfizer’s cholesterol medication are not pre-empted by federal patent law, a New Jersey federal judge has ruled – but state procedural laws impede some of the claims.
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10